^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Herceptin (trastuzumab)

    i
    Other names: R 597, R597, RG597, RG-597, R-597, RG 597
    Company:
    Roche
    Drug class:
    HER2 inhibitor
    Related drugs:
    1d
    Does trastuzumab-related cardiotoxicity influence long-term outcome in patients with HER-2 positive breast cancer? A prospective study. (PubMed, Arch Med Sci)
    In a multivariate regression analysis the cumulative dose of anthracycline (OR = 1.01, 95% CI: 1.00-1.01, p = 0.002) and LVEF at baseline (OR = 0.83, 95% CI: 0.70-0.99, p = 0.0344) were independent predictors of a cardiotoxic effect. Trastuzumab-related cardiotoxicity resulting in early treatment discontinuation negatively influences DFS, but does not seem to influence OS.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab)
    2d
    Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=63, Completed, City of Hope Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 amplification + HR-positive • HER-2 overexpression + HR positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel
    3d
    Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer (clinicaltrials.gov)
    P2, N=124, Recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • trastuzumab rezetecan (SHR-A1811)
    3d
    TACTIC: Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure (clinicaltrials.gov)
    P2, N=224, Terminated, Mayo Clinic | Trial completion date: Feb 2027 --> Feb 2026 | Active, not recruiting --> Terminated; slow accrual; insufficient funding to continue to accrue
    Trial completion date • Trial termination
    |
    Herceptin (trastuzumab)
    3d
    A Case Report: A Rare Casr Mutation Associated with HER2-Positive Breast Cancer. (PubMed, Exp Oncol)
    The patient underwent neoadjuvant chemothera- py, right-sided mastectomy, and trastuzumab therapy, achieving complete pathological regression (pCR) with no recur- rence after ten months of follow-up. Although the CASR p.Glu755Asp variant's pathogenic role is unproven, emerging evidence links CASR overexpression with hER2-positive breast cancers, promoting tumor progression via calcium- dependent signaling pathways (PI3K/AKt, MAPK). This case highlights the potential role of CASR as a low-penetrance susceptibility gene in breast cancer and supports further functional and genomic studies to clarify its clinical impact.
    Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • CHEK2 (Checkpoint kinase 2) • CASR (Calcium Sensing Receptor)
    |
    HER-2 positive • BRCA2 mutation • BRCA1 mutation • HER-2 overexpression • HER-2 mutation • PALB2 mutation • ER negative • CHEK2 mutation • HER-2 positive + HER-2 overexpression
    |
    Herceptin (trastuzumab)
    6d
    MCC-21917: Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer (clinicaltrials.gov)
    P2, N=8, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | N=36 --> 8
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • 5-fluorouracil • Nerlynx (neratinib) • oxaliplatin • leucovorin calcium
    7d
    JUSTIFY: JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Women's College Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 positive
    |
    Herceptin (trastuzumab)
    7d
    A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=108, Recruiting, Daiichi Sankyo | Active, not recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation • HER-2 expression
    |
    Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • DS-1103
    8d
    Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer. (PubMed, Breast Cancer)
    Eribulin could help avoid the early deteriorations in QoL that occur during taxane therapy and maintain QoL for longer in patents with HER2-positive LABC/MBC receiving trastuzumab and pertuzumab.
    Journal • HEOR
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • eribulin mesylate
    8d
    The impact of the PI3K/AKT/mTOR signaling pathway on trastuzumab resistance in HER2-positive gastric cancer. (PubMed, Clin Transl Oncol)
    This study examines the biological and clinical significance of HER2 in gastric cancer and explores the molecular mechanisms underlying PI3K/Akt/mTOR-mediated resistance to trastuzumab. Furthermore, emerging therapeutic strategies targeting these mechanisms may facilitate the development of effective, personalized treatment approaches for patients with HER2-positive gastric cancer.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 overexpression • HER-2 positive + HER-2 overexpression
    |
    Herceptin (trastuzumab)
    8d
    Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, Sheng Tai
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • AiRuiKa (camrelizumab) • trastuzumab rezetecan (SHR-A1811)
    9d
    Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer (clinicaltrials.gov)
    P2, N=182, Recruiting, Hebei Medical University Fourth Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • paclitaxel • Irene (pyrotinib) • cyclophosphamide • pegylated liposomal doxorubicin